Aratana Therapeutics to Showcase Extensive Clinical Development Pipeline at ACVIM

Veterinary Industry Thought Leaders and Members of Aratana to Highlight Advances in the Treatment of Oncology, Inappetence and Pain for Pets

KANSAS CITY, Kan., May 14, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that data and observational studies resulting from the Company's extensive clinical development pipeline will be featured in multiple oral and poster presentations during the 2015 American College of Veterinary Internal Medicine Forum (ACVIM) in Indianapolis, IN.  The 2015 ACVIM Forum is being held June 3-6, 2015 at the Indiana Convention Center to advance the growth and science of veterinary and animal care.

Showcasing its growing leadership in the development and commercialization of pet medications, Aratana's advancements in the treatment of pet oncology, inappetence and pain will be the subject of 11 presentations during the 2015 ACVIM Forum.  The presentations will be given by veterinary industry experts over the course of the four-day conference:

Cancer Therapies and Clinical Studies

Title:


The Evolving Science of Immunotherapeutics in Veterinary Oncology

Date: 


Thursday, June 4, 2015

Time/Type: 


10:30 am – 11:20 am (Eastern Time) – CE Presentation

Location:


Indiana Convention Center – Sagamore 7

Presenter: 


Philip J. Bergman, DVM, Ph.D., DACVIM (Oncology); and Chad Johannes,

DVM, DACVIM (SAIM, Oncology)




Title:


A Prospective, Open-Label Study Evaluating Treatment of Canine B-cell Lymphoma with L-Asparaginase, Doxorubicin and a Canine Anti-CD20 Monoclonal Antibody

Date: 


Thursday, June 4, 2015

Time/Type: 


11:00 am – 11:15 am (Eastern Time) – Abstract Presentation

Location:


Indiana Convention Center – Room 233

Presenter:


Carlos O. Rodriguez, Jr., DVM, Ph.D., DACVIM (Oncology)




Title:


Clinical Application of Immunotherapeutics in Veterinary Oncology

Date: 


Thursday, June 4, 2015

Time/Type: 


11:30 am – 12:20 pm (Eastern Time) – CE Presentation

Location:


Indiana Convention Center – Sagamore 7

Presenter:


Philip J. Bergman, DVM, Ph.D., DACVIM (Oncology); and Chad Johannes,



DVM, DACVIM (SAIM, Oncology)




Title:


Anti-CD20 Monoclonal Antibody Canine Lymphoma Therapy: A Double-Blind, Randomized, Placebo-Controlled Study

Date: 


Friday, June 5, 2015

Time/Type: 


5:25 pm – 5:50 pm (Eastern Time) – Research Report Presentation

Location:


Indiana Convention Center – Room 201

Presenter:


Gregory Ogilvie, DACVIM (SAIM, Oncology), DECVIM-CA (Oncology)




Title:


Combination Listeria-Based Immunotherapy Plus Palliative Radiation Delays Tumor Progression and Prolongs Overall Survival in Canine Osteosarcoma

Date: 


Saturday, June 6, 2015

Time/Type: 


8:00 am (Eastern Time) – Late-Breaking Abstract Presentation

Location:


Indiana Convention Center – Room 204

Presenter:


Nicola Mason, BVetMed, Ph.D., DACVIM (SAIM)

 

Inappetence Solutions in Development

Title:


Safety of the Ghrelin Agonist, Capromorelin, Administered Daily to Beagle Dogs for One Year

Date: 


Thursday, June 4, 2015

Time/Type: 


10:30 am – 10:45 am (Eastern Time) – Abstract Presentation

Location:


Indiana Convention Center – Room 231

Presenter:


Linda Rhodes, VMD, Ph.D.




Title:


Capromorelin, An Orally Active Ghrelin Agonist, Caused Sustained Increases in IGF-1, Increased Food Intake and Body Weight in Cats

Date: 


Friday, June 5, 2015

Time/Type: 


6:00 pm – 7:30 pm (Eastern Time) – Abstract Poster Session

Location:


Indiana Convention Center – Hall C

Presenter:


Bill Zollers, Ph.D.




Title:


Safety of the Ghrelin Agonist, Capromorelin, Administered to Cats for 91 Days at an Oral Dose of 6 mg/kg

Date: 


Friday, June 5, 2015

Time/Type: 


6:00 pm – 7:30 pm (Eastern Time) – Abstract Poster Session

Location:


Indiana Convention Center – Hall C

Presenter:


Julie Allen, BVMS, MS, MRCVS, DACVIM (SAIM)




Title:


New Therapeutic Advances in Inappetence for Pets

Date: 


Friday, June 5, 2015

Time/Type: 


6:30 am – 8:00 am (Eastern Time) – Special Breakfast Session

Location:


Indiana Convention Center – Room 123-124

Presenter:


Audrey Cook, BVM&S, MRCVS, DACVIM, (SAIM), DECVIM (CA), DABVP    
(Feline); and Julie Allen, BVMS, MS, MRCVS, DACVIM (SAIM)

 

Pain Management Treatment Advances

Title:


Introduction to the Emerging Piprant Therapeutic Class of Prostanoid Receptor Antagonists

Date: 


Friday, June 5, 2015

Time/Type: 


9:00 am – 9:50 am (Eastern Time) – CE Presentation

Location:


Indiana Convention Center – Sagamore 1

Presenter:


Kristin Kirkby Shaw, DVM, MS, Ph.D., DACVS, DACVSMR




Title:


Safety and Toxicokinetic Profiles in Cats Administered Grapiprant, A Selective Prostaglandin-Receptor Antagonist

Date: 


Friday, June 5, 2015

Time/Type: 


6:00 pm – 7:30 pm (Eastern Time) – Abstract Poster Session

Location:


Indiana Convention Center – Hall C

Presenter:


Lesley Rausch-Derra, DVM, MS

 

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts:

For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
ctooman@aratana.com; (913) 353-1026

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.

print email rss